<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11590">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02956057</url>
  </required_header>
  <id_info>
    <org_study_id>BN102016</org_study_id>
    <nct_id>NCT02956057</nct_id>
  </id_info>
  <brief_title>Polyethylene Glycol Versus Low Volume Solutions Prior to Colonoscopy</brief_title>
  <official_title>A Head-to-head Comparison of Efficiency and Tolerance of 4-L Polyethylene Glycol and Sodium Picosulphate/ Magnesium Citrate, Polyethylene Glycol/Ascorbate Before Colonoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tomas Bata Hospital, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brno University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Faculty Hospital Kralovske Vinohrady</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tomas Bata Hospital, Czech Republic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study evaluates the efficacy and tolerability of low volume preparations compared with
      conventional 4L polyethylene glycol prior to colonoscopy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the efficacy and tolerance of standard polyethylene glycol to low volume sodium
      picosulphate/magnesium citrate and polyethylene glycol/ascorbic acid in a single or split
      dose regimen for colonoscopy bowel preparation in a head-to-head design.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of bowel preparation using the Aronchick scale ( score 1+2)</measure>
    <time_frame>One day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerance of bowel preparation assessed by 5 point VAS ( score 1+2)</measure>
    <time_frame>One day</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">840</enrollment>
  <condition>Colonoscopy</condition>
  <arm_group>
    <arm_group_label>PEG1D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Polyethylene glycols single dose a day before colonoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG2D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Polyethylene glycols split dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPMC1D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Natrium picosulfate/ Magnesium citrate single dose day before colonoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPMC2D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Natrium picosulfate/ Magnesium citrate split dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEGA1D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Polyethylene glycol / Ascorbic acid single dose day before colonoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEGA2D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Polyethylene glycol / Ascorbic acid split dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyethylene Glycols</intervention_name>
    <arm_group_label>PEG1D</arm_group_label>
    <arm_group_label>PEG2D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Natrium picosulfate / Magnesium citrate</intervention_name>
    <arm_group_label>SPMC1D</arm_group_label>
    <arm_group_label>SPMC2D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyethylene glycol / Ascorbic acid</intervention_name>
    <arm_group_label>PEGA1D</arm_group_label>
    <arm_group_label>PEGA2D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects referred to diagnostic or therapeutic colonoscopy

        Exclusion Criteria:

          -  ileus

          -  known or suspected bowel obstruction

          -  active bowel inflammation

          -  pregnancy

          -  any presence of serious medical conditions

          -  history of prior colonic or rectal surgery

          -  inability to obtain valid data from subject
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladimir Kojecky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nemocnice T.Bati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vladimir Kojecky, MD</last_name>
    <phone>+420577552512</phone>
    <email>kojecky@bnzlin.cz</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty Hospital Kralovske Vinohrady</name>
      <address>
        <city>Prague</city>
        <zip>10024</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan Matous, MD</last_name>
      <phone>+420267163680</phone>
      <email>jan.matous1@fnkv.cz</email>
    </contact>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 3, 2016</lastchanged_date>
  <firstreceived_date>November 1, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tomas Bata Hospital, Czech Republic</investigator_affiliation>
    <investigator_full_name>Vladimir Kojecky, MD, Ph.D.</investigator_full_name>
    <investigator_title>MUDr.</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Picosulfate sodium</mesh_term>
    <mesh_term>Magnesium citrate</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
